CY1123982T1 - Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) - Google Patents
Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ)Info
- Publication number
- CY1123982T1 CY1123982T1 CY20211100276T CY211100276T CY1123982T1 CY 1123982 T1 CY1123982 T1 CY 1123982T1 CY 20211100276 T CY20211100276 T CY 20211100276T CY 211100276 T CY211100276 T CY 211100276T CY 1123982 T1 CY1123982 T1 CY 1123982T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- multiple myeloma
- administered
- patient
- effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Display Devices Of Pinball Game Machines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167597 | 2015-05-13 | ||
| PCT/EP2016/060810 WO2016180958A1 (en) | 2015-05-13 | 2016-05-13 | Treatment for multiple myeloma (mm) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123982T1 true CY1123982T1 (el) | 2022-05-27 |
Family
ID=53174925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100276T CY1123982T1 (el) | 2015-05-13 | 2021-03-30 | Θεραπευτικη αγωγη για το πολλαπλο μυελωμα (μμ) |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10533057B2 (enExample) |
| EP (1) | EP3294769B1 (enExample) |
| JP (2) | JP7160533B2 (enExample) |
| KR (1) | KR20180008571A (enExample) |
| CN (1) | CN107614530A (enExample) |
| AU (1) | AU2016260895B2 (enExample) |
| CA (1) | CA2984464C (enExample) |
| CY (1) | CY1123982T1 (enExample) |
| DK (1) | DK3294769T3 (enExample) |
| ES (1) | ES2862708T3 (enExample) |
| HR (1) | HRP20210552T1 (enExample) |
| HU (1) | HUE054271T2 (enExample) |
| IL (1) | IL255552B (enExample) |
| LT (1) | LT3294769T (enExample) |
| MX (1) | MX380557B (enExample) |
| PL (1) | PL3294769T3 (enExample) |
| PT (1) | PT3294769T (enExample) |
| RS (1) | RS61668B1 (enExample) |
| RU (1) | RU2723047C2 (enExample) |
| SG (1) | SG11201708691VA (enExample) |
| SI (1) | SI3294769T1 (enExample) |
| SM (1) | SMT202100202T1 (enExample) |
| WO (1) | WO2016180958A1 (enExample) |
| ZA (1) | ZA201708386B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10533057B2 (en) * | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| CA3095086A1 (en) * | 2018-03-28 | 2019-10-03 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| MX2021007047A (es) * | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
| IL285110B2 (en) * | 2019-01-28 | 2025-11-01 | Sanofi Sa | Methods of treating multiple myeloma |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| EP2915820A1 (en) | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anti-CD38 human antibodies and uses therefor |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN101287764B (zh) | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2007281684C1 (en) * | 2006-08-07 | 2013-12-19 | Abbvie Biotherapeutics Inc. | Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2580243B1 (en) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| US9738933B2 (en) * | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
| CN103421115B (zh) * | 2013-09-02 | 2015-06-03 | 东南大学 | 一种cd38纳米抗体及应用 |
| MX373301B (es) * | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| US10533057B2 (en) * | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
-
2016
- 2016-05-13 US US15/569,495 patent/US10533057B2/en active Active
- 2016-05-13 LT LTEP16723349.3T patent/LT3294769T/lt unknown
- 2016-05-13 SG SG11201708691VA patent/SG11201708691VA/en unknown
- 2016-05-13 CA CA2984464A patent/CA2984464C/en active Active
- 2016-05-13 SI SI201631139T patent/SI3294769T1/sl unknown
- 2016-05-13 MX MX2017014396A patent/MX380557B/es unknown
- 2016-05-13 DK DK16723349.3T patent/DK3294769T3/da active
- 2016-05-13 RU RU2017137496A patent/RU2723047C2/ru active
- 2016-05-13 HU HUE16723349A patent/HUE054271T2/hu unknown
- 2016-05-13 ES ES16723349T patent/ES2862708T3/es active Active
- 2016-05-13 PT PT167233493T patent/PT3294769T/pt unknown
- 2016-05-13 KR KR1020177035726A patent/KR20180008571A/ko not_active Ceased
- 2016-05-13 PL PL16723349T patent/PL3294769T3/pl unknown
- 2016-05-13 HR HRP20210552TT patent/HRP20210552T1/hr unknown
- 2016-05-13 CN CN201680027238.0A patent/CN107614530A/zh active Pending
- 2016-05-13 JP JP2017558542A patent/JP7160533B2/ja active Active
- 2016-05-13 EP EP16723349.3A patent/EP3294769B1/en active Active
- 2016-05-13 AU AU2016260895A patent/AU2016260895B2/en active Active
- 2016-05-13 WO PCT/EP2016/060810 patent/WO2016180958A1/en not_active Ceased
- 2016-05-13 SM SM20210202T patent/SMT202100202T1/it unknown
- 2016-05-13 RS RS20210419A patent/RS61668B1/sr unknown
-
2017
- 2017-11-09 IL IL255552A patent/IL255552B/en unknown
- 2017-12-11 ZA ZA2017/08386A patent/ZA201708386B/en unknown
-
2019
- 2019-11-25 US US16/693,904 patent/US11591406B2/en active Active
-
2021
- 2021-03-30 CY CY20211100276T patent/CY1123982T1/el unknown
- 2021-05-06 JP JP2021078658A patent/JP2021130668A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| CY1126036T1 (el) | Δοσολογικο σχημα σακουμπιτριλης-βαλσαρτανης για τη θεραπευτικη αντιμετωπιση της καρδιακης ανεπαρκειας | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1121360T1 (el) | Αναστολεις dna-pk | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| JOP20190194B1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| CY1122469T1 (el) | Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης | |
| EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
| CL2021001025A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| CY1121436T1 (el) | Δοσολογια για τους αναστολεις των kinασων janus (jak) | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| EA201692512A1 (ru) | Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| MX373373B (es) | Inhibidores de desmetilasa-1 específica de lisina. | |
| PT3826639T (pt) | Dosagem otimizada de diaminofenotiazinas em populações | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| GEAP201813996A (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| MX2017014396A (es) | Tratamiento de mieloma multiple. | |
| LT3488443T (lt) | Neoepitopų, kaip ligai specifinių taikinių, parinkimas padidinto efektyvumo terapijai | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы |